Figure 1
Chemotherapy delivery in US and EU patients. Incidence of dose delays > 3 days in any cycle, dose reductions > 10% in any drug in any cycle, and RDI ≤ 85% compared to either planned RDI or standard ABVD in US (N = 68) and EU (N = 47) patients during the first 4 cycles of chemotherapy. Error bars represent 95% CIs. *Assessment took into account administered cycles only; ¶Disregarding vinblastine; ‡EBVD patients excluded (US N = 67, EU N = 44); Standard ABVD: bleomycin 5 units/m2/week, doxorubicin 12.5 mg/m2/week, dacarbazine 187.5 mg/m2/week, vinblastine 3 mg/m2/week. RDI relative dose intensity; ABVD doxorubicin, bleomycin, vinblastine and dacarbazine; CI confidence interval; EBVD epirubicin, bleomycin, vinblastine and dacarbazine.